existing drugs has led to high mortality in patients with serious fungal infections. To develop novel antifungal therapeutic strategies, herein a series of carboline fungal histone deacetylase (HDAC) inhibitors were designed and synthesized, which had potent synergistic effects with fluconazole against resistant Candida albicans infection. In particular, compound D12 showed excellent in vitro and in vivo
由于抗真菌药耐药性的发展和发展,现有药物的有限功效导致严重真菌感染患者的高死亡率。为了开发新的抗真菌治疗策略,本文设计并合成了一系列咔啉类真菌组蛋白脱乙酰基酶(H
DAC)
抑制剂,它们与
氟康唑对耐药性白色念珠菌感染具有有效的协同作用。特别地,化合物D12与
氟康唑一起显示出优异的体外和体内协同抗真菌功效,以治疗耐唑类念珠菌病。它与
氟康唑合作降低了白色念珠菌的毒力通过阻止形态学相互转化和抑制
生物膜形成。机制研究表明,耐药性的逆转是由于唑靶
基因ERG11和外排
基因CDR1的表达下调。总之,真菌H
DAC抑制剂D12提供了一种有前途的
铅化合物,可用于抗唑类念珠菌病的联合治疗。